Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic
fatty liver disease (NAFLD) is increasing both in Europe and the United States, becoming …

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver
disease in industrialized countries worldwide, and has become a serious public health issue …

This practice guideline has been approved by the American Association for the Study of
Liver Diseases and the American Society of Transplantation. These recommendations …

Obesity is increasingly common before and after liver transplantation (LT), yet optimal
management remains unclear. Our aim was to analyze the effectiveness of a …

Non-alcoholic fatty liver disease (NAFLD) is an important health problem worldwide. NAFLD
encompasses a histological spectrum ranging from bland liver steatosis to severe …

The rising tide of non-alcoholic fatty liver disease (NAFLD) associated with the obesity
epidemic is a major health concern worldwide. NAFLD—specifically its more advanced form …

Background. The true incidence and unique risk factors for recurrent and de novo
nonalcoholic fatty liver (NAFLD) and nonalcoholic steatohepatitis (NASH) post-liver …

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver
transplantation (LT) in Western Countries, both for end stage liver disease and …

Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a
challenging and multisystem disease that has a high socioeconomic impact. NAFLD/NASH …

Background Morbid obesity is a relative contraindication for organ transplant because it is
associated with higher postoperative morbidity and mortality. The safety and efficacy of …